BioTime, Inc., חברת ביוטק בשלב הקליני
שמתמקדת במחלות ניווניות, הודיעה היום שהצהרת הרישום על גבי טופס 10, כולל הצהרת
המידע שמתייחסת לחלוקה שהוכנה והוגשה קודם לכן על ידי AgeX
Therapeutics, Inc. (“AgeX”),
הוכרזה כתקפה על ידי הרשות האמריקנית לניירות ערך (“SEC”)
ב-27 בנובמבר 2018, וביוטיים תמשיך עם החלוקה של בערך 12.7 מיליון מניות AgeX
שבבעלות ביוטיים על בסיס שיעור יחסי, לבעלי מניות זכאים של ביוטיים החל משעה 17:00
שעון החוף המזרחי היום. בעלי מניות זכאים של ביוטיים זכאים במסגרת החלוקה לקבל
מניה רגילה אחת של AgeX עבור כל 10 מניות רגילות של ביוטיים
שמוחזקות בתאריך הרישום של 16 בנובמבר 2018.
BioTime Announces Distribution of AgeX Therapeutics Shares
- Distribution to Commence Today at 5:00pm ET
- Trading to Commence on November 29th, 2018 Under the Symbol “AGE”
ALAMEDA, Calif., 28 NOV 2018, (BUSINESS WIRE):
BioTime, Inc. (NYSE American and TASE: BTX), a
clinical-stage biotechnology company focused on degenerative diseases, today
announced that the registration statement on Form 10, including the information
statement relating to the distribution that was previously prepared and filed
by AgeX Therapeutics, Inc. (“AgeX”), was declared effective by the Securities
and Exchange Commission (“SEC”) on November 27, 2018, and that BioTime will
proceed with the distribution of approximately 12.7 million AgeX shares owned
by BioTime on a pro rata basis, to eligible BioTime shareholders beginning at
5:00pm ET today. Eligible BioTime shareholders are entitled under the
distribution to receive one share of AgeX common stock for every 10 shares of
BioTime common stock held as of the record date of November 16, 2018.
BioTime
shareholders are not required to take any action to receive the AgeX
distribution. However, BioTime recommends that its
shareholders contact their respective brokers to ensure and confirm proper
delivery of the AgeX shares into their accounts.
Because
BioTime shares have traded with due-bills since the record date, any parties
that bought or sold BioTime shares between the record date and the distribution
date also bought or sold their right to receive the distribution of AgeX
shares.
AgeX
common stock has been approved for listing on the NYSE American under the
ticker symbol AGE. AgeX shares will not trade on a “when-issued” basis, but
will begin trading the “regular way” on Thursday, November 29, 2018. BioTime
will begin trading “ex-distribution,” or without the right to receive the
distribution, on Thursday, November 29, 2018. The NYSE
will not make a distribution price adjustment to the BioTime shares that trade on
the exchange.
For
more detail on AgeX’s business, risk factors, and uncertainties, shareholders
should carefully review the Information Statement filed with the SEC and
available at the SEC website at www.sec.gov.
This
announcement shall not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.
About
AgeX Therapeutics
AgeX
Therapeutics, Inc. is a biotechnology company focused on the development of
novel therapeutics for age-related degenerative disease. The current
development efforts include two cell-based therapies derived from pluripotent
stem cells and two product candidates derived from the company’s proprietary
induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are
cell-based approaches in the preclinical stage of development comprised of
young regenerative cells modified using the Company’s UniverCyte™ technology
facilitating immune tolerance, formulated in HyStem® matrix, designed to
correct metabolic imbalances in aging and to restore vascular support in
ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in
preclinical development intended to restore regenerative potential in a wide
array of aged tissues afflicted with degenerative disease using the company’s
proprietary iTR technology. Renelon™ is a first-generation iTR product designed
to promote scarless tissue repair which the Company plans to initially develop
as a topically-administered device for commercial development through a 510(k)
application. In addition to the product candidates in early development, the
company, through its LifeMap subsidiary, currently markets genomic
interpretation algorithms. In addition, the company, through its ESI
BIOdivision, markets Cytiva®, comprised of PSC-derived heart muscle
cells used in screening drugs for efficacy and safety. For more information,
please visit www.agexinc.com or
connect with the company on Twitter, Facebook and YouTube.
About
BioTime, Inc.
BioTime is
a clinical-stage biotechnology company focused on the development and commercialization
of novel therapies for the treatment of degenerative diseases. BioTime’s
pipeline is based on two platform technologies which encompass cell replacement
and cell/drug delivery. BioTime’s lead cell replacement product candidate is
OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2
development for the treatment of dry age-related macular degeneration, the
leading cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical device
being developed as an alternative for whole adipose tissue transfer procedures.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
LinkedIn,
Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications, please click on
the following link to join the Company’s email alert list: http://news.biotime.com.
Forward-Looking
Statements
Certain
statements contained in this release are “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not historical fact including, but not limited to
statements that contain words such as “will,” “believes,” “plans,”
“anticipates,” “expects,” “estimates” should also be considered forward-looking
statements. Investors are cautioned that statements in this press release
regarding: (a) any value to BioTime shareholders of the AgeX common stock and
(b) BioTime's plans or expectations for the distribution, constitute
forward-looking statements. Forward-looking statements involve risks and
uncertainties. These risks and uncertainties, include, without limitation: (i)
the possibility that BioTime shareholders may realize little or no value from
the AgeX common stock; (ii) the potential inability of BioTime to complete
distribution in a timely manner; and (iii) the possibility of litigation that
could arise as a result of or in connection with the distribution and related
transactions. Actual results may differ materially from the results anticipated
in these forward-looking statements and as such should be evaluated together
with the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements found
in more detail in the “Risk Factors” section of BioTime’s Annual Reports on
Form 10-K and Quarterly Reports on Form 10-Q and AgeX Form 10 and Information
Statement filed with the SEC (copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking statements
to change. BioTime specifically disclaims any obligation or intention to update
or revise these forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as required by
applicable law.
אין תגובות:
הוסף רשומת תגובה
שים לב: רק חברים בבלוג הזה יכולים לפרסם תגובה.